Results 141 to 150 of about 3,643,296 (309)
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui +10 more
wiley +1 more source
Aestimatio volume 12 (2015) complete [PDF]
Alan C. Bowen and Tracey E. Rihll edd.
doaj
Corrigendum to "Combining methods to conduct a systematic review and propose a conceptual and theoretical framework in socio-environmental research" [MethodsX (2024) 1-19/Volume 12, 102484]. [PDF]
Eyzaguirre IAL, Fernandes MEB.
europepmc +1 more source
Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268]. [PDF]
Golob-Schwarzl N +27 more
europepmc +1 more source
Development of human monoclonal antibodies against TARM1 by yeast display
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe +5 more
wiley +1 more source
Morphometric evaluation of middle ear anatomical structures using full volume (12 × 9) CBCT scans: A retrospective study in Navi Mumbai. [PDF]
Verma SN, Patil BS, Das DA.
europepmc +1 more source
Screening and epitope characterization of Nidogen‐2‐specific nanobodies
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen +9 more
wiley +1 more source
Various Authors
doaj +1 more source
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel +8 more
wiley +1 more source

